Nicox: 2024 Ordinary Shareholder Meeting
27 Juni 2024 - 5:30PM
Nicox: 2024 Ordinary Shareholder Meeting
Press Release |
Nicox: 2024 Ordinary Shareholder Meeting |
June
27, 2024 – release at 17:30 CET Sophia Antipolis,
FranceNicox SA (Euronext Paris: FR0013018124,
ALCOX), an international ophthalmology company, informs its
shareholders that the Ordinary general meeting convened on first
call on Friday June 28, 2024, will not be held as the quorum
required by law has not been reached.The shareholders of Nicox are
thus convened on second call for an Ordinary general meeting on the
same resolutions and the same agenda on Monday July 15 at
2:30 pm CET in the offices of BuroClub - Drakkar 2
- Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia
Antipolis - France.The documents relating to the general
meeting, including the draft resolutions and the proxy form, are
made available to shareholders at the headquarters of the Company
and on its website (www.nicox.com).Shareholders may vote by proxy,
by internet or by attending the Ordinary shareholder meeting in
person. A guide explaining how to vote, and notably how to vote by
internet, is posted on Nicox’s website. Shareholders may also
contact the Company’s Investor Relations team at
ag2024nicox@nicox.com for any question on the voting process. The
proxy forms sent by correspondence, or the electronic votes
received for the Ordinary general meeting initially planned on June
28, 2024 remain valid for the Ordinary general meeting of July 15,
2024. |
About Nicox |
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX
470, a novel nitric oxide-donating bimatoprost eye drop, for
lowering intraocular pressure in patients with open-angle glaucoma
or ocular hypertension. Nicox generates revenue from VYZULTA®
in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and
ZERVIATE® in allergic conjunctivitis, licensed in multiple
geographies, including to Harrow, Inc. in the U.S., and Ocumension
Therapeutics in the Chinese and in the majority of Southeast Asian
markets. Nicox, headquartered in Sophia Antipolis, France, is
listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part
of the CAC Healthcare index. For more information
www.nicox.com. |
Analyst coverage |
H.C. Wainwright &
Co Yi
Chen New York,
U.S. |
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
Contacts |
|
NicoxGavin SpencerChief Executive Officer+33 (0)4
97 24 53 00communications@nicox.com |
Media / Investors Sophie Baumont Cohesion Bureau
+33 6 27 74 74 49 sophie.baumont@cohesionbureau.com |
Disclaimer |
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.Risks factors which are likely to have a material effect
on Nicox’s business are presented in section 3 of the “Rapport
Annuel 2023” which is available on Nicox’s website
(www.nicox.com).Finally, this press release may be drafted in the
French and English languages. If both versions are interpreted
differently, the French language version shall prevail. |
Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C,
Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4
97 24 53 00 |
- EN_AGO June 2024_quorum not reached PR_20240409_FINAL
Nicox (EU:ALCOX)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Nicox (EU:ALCOX)
Historical Stock Chart
Von Nov 2023 bis Nov 2024